CR9293A - USE OF RIMONABANT FOR THE PREPARATION OF USEFUL DRUGS IN THE PREVENTION AND TREATMENT OF TYPE 2 DIABETES - Google Patents

USE OF RIMONABANT FOR THE PREPARATION OF USEFUL DRUGS IN THE PREVENTION AND TREATMENT OF TYPE 2 DIABETES

Info

Publication number
CR9293A
CR9293A CR9293A CR9293A CR9293A CR 9293 A CR9293 A CR 9293A CR 9293 A CR9293 A CR 9293A CR 9293 A CR9293 A CR 9293A CR 9293 A CR9293 A CR 9293A
Authority
CR
Costa Rica
Prior art keywords
diabetes
prevention
preparation
treatment
type
Prior art date
Application number
CR9293A
Other languages
Spanish (es)
Inventor
Corinne Hanotin
Pierre Rosenzweig
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0501861A external-priority patent/FR2882261B1/en
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of CR9293A publication Critical patent/CR9293A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Utilizacion de rimonabant a solas o asociado con otro principio activo, para la preparacion de medicamentos utiles en la prevencion y el tratamiento de la diabetes de tipo 2 o la diabetes no insulino-dependiente y/o de sus complicaciones.Use of rimonabant alone or in association with another active substance, for the preparation of useful medicines in the prevention and treatment of type 2 diabetes or non-insulin-dependent diabetes and / or its complications.

CR9293A 2005-02-21 2007-08-07 USE OF RIMONABANT FOR THE PREPARATION OF USEFUL DRUGS IN THE PREVENTION AND TREATMENT OF TYPE 2 DIABETES CR9293A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0501861A FR2882261B1 (en) 2005-02-21 2005-02-21 USE OF A PYRAZOLE DERIVATIVE FOR THE PREPARATION OF MEDICAMENTS USEFUL IN THE PREVENTION AND TREATMENT OF TYPE 2 DIABETES
FR0504942A FR2882264A1 (en) 2005-02-21 2005-05-12 Use of rimonabant and N-peperidino-5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethylpyrazole-3-carboxamide, having cannabinoids receptor antagonistic activity, to treat and prevent type-II diabetes
FR0505228A FR2882265B1 (en) 2005-02-21 2005-05-23 USE OF A PYRAZOLE DERIVATIVE FOR THE PREPARATION OF MEDICAMENTS USEFUL IN THE PREVENTION AND TREATMENT OF TYPE 2 DIABETES.

Publications (1)

Publication Number Publication Date
CR9293A true CR9293A (en) 2007-10-01

Family

ID=36809538

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9293A CR9293A (en) 2005-02-21 2007-08-07 USE OF RIMONABANT FOR THE PREPARATION OF USEFUL DRUGS IN THE PREVENTION AND TREATMENT OF TYPE 2 DIABETES

Country Status (10)

Country Link
JP (1) JP2008530189A (en)
BR (1) BRPI0608183A2 (en)
CR (1) CR9293A (en)
EA (1) EA011618B1 (en)
FR (2) FR2882264A1 (en)
IL (1) IL185401A0 (en)
MA (1) MA29262B1 (en)
MX (1) MX2007009996A (en)
TN (1) TNSN07297A1 (en)
TW (1) TW200640457A (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2789079B3 (en) * 1999-02-01 2001-03-02 Sanofi Synthelabo PYRAZOLECARBOXYLIC ACID DERIVATIVE, ITS PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
US20040122033A1 (en) * 2002-12-10 2004-06-24 Nargund Ravi P. Combination therapy for the treatment of obesity

Also Published As

Publication number Publication date
TNSN07297A1 (en) 2008-12-31
TW200640457A (en) 2006-12-01
FR2882264A1 (en) 2006-08-25
EA200701781A1 (en) 2007-12-28
JP2008530189A (en) 2008-08-07
BRPI0608183A2 (en) 2009-11-17
MX2007009996A (en) 2007-10-10
EA011618B1 (en) 2009-04-28
MA29262B1 (en) 2008-02-01
FR2882265A1 (en) 2006-08-25
IL185401A0 (en) 2008-08-07
FR2882265B1 (en) 2009-02-13

Similar Documents

Publication Publication Date Title
BRPI0815577A2 (en) FOXM1 PEPTIDE AND MEDICAL AGENT UNDERSTANDING THE SAME.
HK1121074A1 (en) Treatment of type 2 diabetes with a combination of dpiv inhibitor and metformin or thiazolidinedione
MA28921B1 (en) NITROGENIC HETEROCYCLIC DERIVATIVE AND MEDICINE CONTAINING THE SAME AS ACTIVE INGREDIENT
BRPI0615150A2 (en) agent for the prophylaxis or treatment of diabetes, insulin sensitizer, compound, prodrug, pharmaceutical agent, and use of the compound or a salt thereof or a prodrug thereof
EA201100621A1 (en) TREATMENT OF DIABETES IN PATIENTS IN WHICH ARE INSUFFICIENT GLYCEMIC CONTROL OBSERVING THEREOF WITH ORAL OR NON-ORAL ANTI-DIABETIC MEDICINE
ES2376043T3 (en) INDAZOL DERIVATIVES FOR THE TREATMENT OF DISEASES INDUCED BY HSP90.
CL2008002871A1 (en) Oxadiazole-benzimidazole derived compounds; Pharmaceutical composition containing them and their use as dgt1 inhibitors for the treatment of impaired glucose tolerance, type 2 diabetes, and obesity.
PA8637301A1 (en) DERIVATIVES OF AMINO-5, 5-DIFENYLIMIDAZOLONE FOR THE INHIBITION OF THE B-SECRETASE
IL184051A (en) Acylated glp-1 compounds, pharmaceutical compositions comprising them and their use in the manufacture of medicaments
SV2006002100A (en) TREATMENT OF DISRUPTION HEMORRAGY IN EXTENDED CONTRACEPTIVE REGIMES REF. P-SV-78.159 / MSU
CL2007001724A1 (en) USE OF A STROGEN FOR THE TREATMENT OF DISEASES, CONDITIONS OR SYMPTOMS ASSOCIATED WITH DEFICIENT LEVELS OF STROGENS IN A WOMAN; PHARMACEUTICAL COMPOSITION THAT INCLUDES DAILY DOSAGE UNITS OF ESTRADIOL HEMIDRATE> 0.75 AND 1
AR037407A1 (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF MELLITUS TYPE II DIABETES
CL2008002162A1 (en) Compounds derived from 3-benzoisoxazole-piperidine; pharmaceutical composition comprising said compounds; and its use for the treatment and / or prevention of cognitive disorders, drug addiction, depression, anxiety, among others.
CL2007002890A1 (en) Compounds derived from 2-pyridinecarboxamide, glucosinase activator; pharmaceutical composition; and use of the compound for the treatment of diabetes or obesity.
CL2008000610A1 (en) COMPOSITION IN THE FORM OF TRANSDERMIC OR TRANSMUCOSE DOSAGE THAT INCLUDES A RELATIONSHIP IN BUPRENORFINE WEIGHT TO NALOXONE BETWEEN 2.1: 1 AND 8: 1, USEFUL FOR THE TREATMENT OF PAIN.
CL2007002875A1 (en) Pharmaceutical composition covered by a film comprising capecitabine and at least one disintegrant, useful in the treatment of cancer for patients who have difficulty swallowing oral solid dosage forms.
BRPI0717369A2 (en) COMPOUND, MEDICINAL PRODUCT, PHARMACEUTICAL COMPOSITION CONTAINING AND USE OF THE COMPOUND.
CO6640324A2 (en) Use of metformin in combination with a glucokinase activator and compositions comprising metformin and a glucokinase activator
ATE392889T1 (en) ORAL ANTIMICROBIAL PHARMACEUTICAL COMPOSITIONS
CO6321285A2 (en) USE OF 3,11B-CIS- DIHIDROTETRABENAZINE IN THE TREATMENT OF MULTIPLE SCLEROSIS AND SELF-IMMUNE HONEY MIELITIS
CL2007003643A1 (en) PHARMACEUTICAL COMPOSITION OF AZIMILIDINE THAT INCLUDES 0.5% TO APPROXIMATELY 2.5% (W / W) OF WATER; AND USE FOR THE TREATMENT OF CARDIAC ARRITMIAS.
CL2017002293A1 (en) Treatment of patients with type 2 diabetes mellitus
AR050696A1 (en) PHARMACEUTICAL COMPOSITION IN THE FORM OF A COMPRESSED GASTRIC RESIDENCE CONTAINING AN ACTIVE PRINCIPLE
CL2013000709A1 (en) Composition containing nifurtimox and an anthelmintic selected from: pf1022, emopdepside, tribendimidine, amidantel, bay d 9216, praziquantel or benzyl benzoate; useful in the treatment of diseases caused by giardias (div. sol. 1577-10).
CL2008000607A1 (en) ANALGESIC COMPOSITION IN THE FORM OF UNIT PARENTERAL DOSAGE OR IN A SUITABLE UNIT DOSAGE FORM FOR AN ADMINISTRATION BY THE MUCOSA OR THE DERMIS THAT INCLUDES BUPRENORFINE AND NALMEN, USEFUL FOR THE TREATMENT OF PAIN.